Skip to main content
Clinical Trials/ACTRN12615000571572
ACTRN12615000571572SuspendedPhase 1

The effectiveness of a combination of Metformin and Atrovastatin compared with each drug alone and placebo in modulating tumour aggressiveness in men with high risk prostate cancer undergoing radical prostatectomy

niversity of Queensland Centre for Clinical Research0 sites80 target enrollmentStarted: June 3, 2015Last updated:
Conditions

Trial Snapshot

Phase
Phase 1
Status
Suspended
Sponsor
Enrollment
80

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomised controlled trial
Primary Purpose
Treatment
Masking
Blinded (masking used)

Eligibility Criteria

Ages
40 Years to 80 Years (—)
Sex
Male

Inclusion Criteria

  • Patients will be eligible for the trial if they are adult men aged 40 to 80 years who have a PI-RADSv2 (Prostate Imaging-Reporting and Data System) score of 4 or 5 and proceed to prostate biopsy with an intention of having a prostatectomy for confirmed high-risk prostate cancer

Exclusion Criteria

  • Participants will be ineligible for the trial if they:
  • - have been taking any lipid (fats) or cholesterol-lowering medication or blood-glucose (sugar level)-lowering drugs
  • - have experienced any unwanted effects with lipid or glucose-lowering drugs previously
  • - have been considered by their urologist to be unsuitable for the research programme or involvement in the study is not consistent with the patient’s best interests
  • - are taking medications that could cross-react with medications used in the trial

Investigators

Sponsor
niversity of Queensland Centre for Clinical Research

Similar Trials

A Randomised Double-Blind Controlled Trial... | Clinical Trial